|
Brain Ischemia
|
0.510 |
Biomarker
|
disease |
RGD |
[Influence of JDTL injection on inflammatory factors in rat experimental cerebral ischemia].
|
19260320 |
2008 |
|
Pulmonary Hypertension
|
0.500 |
Biomarker
|
phenotype |
RGD |
[Effects of hydrogen sulfide on vascular inflammation in pulmonary hypertension induced by high pulmonary blood flow: experiment with rats].
|
19087668 |
2008 |
|
Tuberculosis, Pulmonary
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
[A promotor polymorphism in monocyte chemoattractant is associated with increased susceptibility to pulmonary tuberculosis].
|
16828028 |
2006 |
|
Metastatic malignant neoplasm to brain
|
0.010 |
Biomarker
|
disease |
BEFREE |
Zhang and colleagues recently demonstrated that astrocyte-derived exosomal miR-19a reversibly downregulated PTEN expression in cancer cells, thereby increasing their CCL2 secretion and recruitment of myeloid cell to promote brain metastasis.
|
26555172 |
2015 |
|
Acute malaria
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Younger children presenting with acute malaria exhibited much higher levels of TNF, IL2, and IL6, as well as increased Th1 associated chemokines IP10, MIG, and MCP1, compared to older children with acute malaria.
|
29284469 |
2017 |
|
Tumor Angiogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
YKL-40 supports tumor angiogenesis by interaction with syndecan-1 on endothelial cells and metastatic spread by stimulating production of pro-inflammatory and pro-invasive factors MMP9, CCL2 and CXCL2.
|
26733160 |
2016 |
|
Metastatic Prostate Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
WNT5A was associated with increased expression of chemokine ligand 2 (CCL2) in the human CaP cell line, LNCaP.
|
29381686 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
WNT5A was associated with increased expression of chemokine ligand 2 (CCL2) in the human CaP cell line, LNCaP.
|
29381686 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
With respect to chronic neuroinflammation, a critical role for MCP-1 has been established in animal models for multiple sclerosis.
|
12556201 |
2003 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
With novel, immunocompetent metastasis models, we demonstrated that tumor cell derived CCL2-mediated recruitment of IMs is necessary and sufficient for LUSC metastasis.
|
29777108 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
With novel, immunocompetent metastasis models, we demonstrated that tumor cell derived CCL2-mediated recruitment of IMs is necessary and sufficient for LUSC metastasis.
|
29777108 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
With a single exception, none of the mice inoculated with cells treated with rAAV expressing HSV-TK + B7.1 or HSV-TK + MCP-1 developed tumour irrespective of GCV treatment.
|
12579310 |
2003 |
|
Sarcoidosis
|
0.040 |
GeneticVariation
|
disease |
LHGDN |
While there was no significant difference in distribution of MCP-1-2518 alleles between sarcoidosis patients and healthy control subjects, a significantly higher proportion of the MCP-1-2518*G allele (p = 0.01, odds ratio (OR) = 2.3) and of the GG genotype (p = 0.03, OR = 3.9) was observed in the patients with LS compared to control subjects.
|
18069417 |
2007 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
While the importance of CCL2/CCR2 signaling in macrophages during cancer progression is well documented, we recently showed that CCL2-mediated breast cancer progression depends on CCR2 expression in carcinoma cells.
|
31208996 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
While the importance of CCL2/CCR2 signaling in macrophages during cancer progression is well documented, we recently showed that CCL2-mediated breast cancer progression depends on CCR2 expression in carcinoma cells.
|
31208996 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
While the importance of CCL2/CCR2 signaling in macrophages during cancer progression is well documented, we recently showed that CCL2-mediated breast cancer progression depends on CCR2 expression in carcinoma cells.
|
31208996 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While our in vitro data support a potential anti-tumor role for CCL2 in TEN neutrophil- mediated tumor killing in poorly aggressive tumors, intranasal delivery of CCL2 increased CD4+ T cell recruitment to the pre-metastatic niche of the lung and this correlated with enhanced seeding and growth of tumor cells.
|
28143493 |
2017 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
While minimally expressed by normal breast epithelial duct cells, both chemokines are highly expressed by breast tumor cells at primary tumor sites, indicating that CCL2 and CCL5 expression is acquired in the course of malignant transformation, and suggesting that the two chemokines play a role in breast cancer development and/or progression.
|
18439751 |
2008 |
|
Kidney Diseases
|
0.300 |
AlteredExpression
|
group |
BEFREE |
While no difference in proportion of samples with detectable uAPRIL was observed between SLE, HCs and IgAN patients, both uAPRIL and uMCP-1 were significantly detectable in higher proportions of patients with active renal disease.
|
30301439 |
2018 |
|
Carcinoma, Lewis Lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
While MCP-1 deficiency reduces metastasis, the elevation of pro-inflammatory cytokines and angiogenic factors in the absence of MCP-1 may support the metastatic development and growth of LLC in MCP-1 deficient mice.
|
27028862 |
2016 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
While MCP-1 deficiency reduces metastasis, the elevation of pro-inflammatory cytokines and angiogenic factors in the absence of MCP-1 may support the metastatic development and growth of LLC in MCP-1 deficient mice.
|
27028862 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Whether CCL2 protumorigenic activities will be validated, then CCL2 and its receptor CCR2 may be therapeutic targets in cancer.
|
28730964 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Whether CCL2 protumorigenic activities will be validated, then CCL2 and its receptor CCR2 may be therapeutic targets in cancer.
|
28730964 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whereas, CM3D was characterised by a prevailing expression of anti-inflammatory cytokines such as IL-10 and LIF, along with trophic factors involved in different mechanisms leading to tissue regeneration, such as PDGF-BB, FGF-2, I-309, SCF, and GM-CSF; CM2D presented relatively higher levels of IL-6, MCP-1, and IL-21, with recognised pro-inflammatory roles in joint disease and pleiotropic effects in the progression of rheumatoid arthritis (RA).
|
30804924 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Whereas AAV-2 vector-mediated transfer of antisense or even ribozyme genes did not significantly influence tumor formation from implanted SiHa cells, the transfer and expression of human MCP-1 strongly inhibited the development of tumors derived from either HeLa or SiHa cells.
|
10830724 |
2000 |